SpringWorks Therapeutics, Inc. (SWTX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 09:56AM EDT. Market open.
| Previous close | 43.38 |
| Open | 42.59 |
| Bid | 43.01 x 400 |
| Ask | 43.57 x 400 |
| Day's range | 41.75 - 43.44 |
| 52-week range | 18.00 - 53.92 |
| Volume | |
| Avg. volume | 1,133,116 |
| Market cap | 3.214B |
| Beta (5Y monthly) | 0.82 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GuruFocus.com
SpringWorks Therapeutics Inc (SWTX) Reports Q4 and Full Year 2023 Financial Results
R&D Expenses: R&D expenses increased to $150.5 million in 2023, reflecting investment in clinical trials and drug development. Net Loss: Net loss widened to $325.1 million in 2023, with a loss per share of $5.15.
- GuruFocus.com
SpringWorks Therapeutics Inc Insider Sells Company Shares
Chief Commercial Officer Bhavesh Ashar has executed a sale of 8,056 shares of SpringWorks Therapeutics Inc (NASDAQ:SWTX) on February 5, 2024, according to a recent SEC filing.
- GuruFocus.com
SpringWorks Therapeutics Inc Chief People Officer Daniel Pichl Sells 26,181 Shares
Daniel Pichl, Chief People Officer of SpringWorks Therapeutics Inc (NASDAQ:SWTX), executed a sale of 26,181 shares in the company on February 2, 2024, according to a recent SEC Filing.
© 2024 Yahoo. All rights reserved.